Table 2.
RCTs Comparing CSII and MDI for T2DM
| |
|
|
|
HbA1c (%) (SD) |
|
||
|---|---|---|---|---|---|---|---|
| Reference | na | Design | Follow-up | Baseline | CSII | MDI | P value |
| Berthe et al.5 | 17 | Crossover | 2 periods of 12 weeks | 9 (1.6) | 7.7 (0.8) | 8.6 (1.6) | < 0.03 |
| Herman et al.6 | 107 | Parallel | 1 year | CSII: 8.4 (1.1) | 6.6 (0.8) | 6.4 (0.8) | 0.19 |
| MDI: 8.1 (1.2) | |||||||
| Raskin et al.7 | 132 | Parallel | 24 weeks | CSII: 8.2 (1.4) | 7.6 (1.2) | 7.5 (1.2) | NS |
| MDI: 8.0 (1.1) | |||||||
| Wainstein et al.8 | 40 | Crossover | 2 periods of 18 weeks | CSII-MDI: 10.1 (1.6) | −0.8 (1.5)b | +0.4 (1.3)b | 0.007 |
| MDI-CSII: 10.2 (1.4) | |||||||
a
Subjects randomized.
b
HbA1c values for CSII and MDI are presented by Wainstein et al.8 as direct treatment effect in the completers' cohort.